Scinus Group announced it has secured a €3 million strategic investment round led by Myosotis Investments to accelerate the global commercial roll-out of its Osilaris™ cell expansion platform and strengthen its governance and operational capabilities.
The investment round was led by Myosotis Investments, the firm founded by biotech entrepreneur Wietse Mulder. Existing shareholders, including the company’s founders and the Demcon Innovation Fund, also participated in the round.
According to the company, the funding marks a key milestone in Scinus’ development and will support the commercialization of the Osilaris™ platform in key markets. The company also said the investment will enhance organizational maturity and governance as it expands globally.
As part of the transaction, Dr. Erik Vossenaar, currently acting managing director of Scinus, will become executive director and CEO. Dr. Janeska de Jonge will join the board as a non-executive director representing Myosotis Investments, with a third board member expected to be appointed later.
Scinus developed the Osilaris™ platform to address manufacturing bottlenecks in cell therapy production. The closed, automated bioreactor system enables dynamic cell expansion as cultures grow, resulting in higher expansion rates than in fixed-volume systems.
The company said its proprietary oxygenation and mixing technology supports gentle, shear-free processing while maintaining precise control over key process parameters. This approach is designed to support sensitive cell types and improve manufacturing consistency.
The platform is fully closed and GMP-compliant, enabling multiple unit operations to be integrated within a single environment. According to Scinus, this reduces contamination risks, lowers manual handling requirements, and decreases both media consumption and labor costs in GMP manufacturing environments.
The Osilaris™ system is already commercially available and installed at several academic advanced therapy medicinal product manufacturers and CDMOs across Europe. It supports applications including CAR-T and CAR-TCR therapies, tumor-infiltrating lymphocytes, mesenchymal stem cells, induced pluripotent stem cells, organoids, viral vector production, and extracellular vesicles.
Scinus Group was established in 2016 following its demerger from Xpand Biotechnology and was founded by Prof. Dr. Joost de Bruijn, Prof. Dr. Clemens van Blitterswijk, and FrankJan van der Velden. Demcon joined the company as a strategic investor and engineering partner in 2019, helping industrialize and commercialize the Osilaris platform.
KEY QUOTES
“Advanced cell therapies require robust and scalable manufacturing solutions. Scinus has developed a differentiated platform that addresses key bottlenecks in control, scalability and cost-efficiency. I am impressed by the technological foundation of Osilaris and the team’s disciplined execution focus. We look forward to supporting Scinus in its next phase of commercial growth.”
Dr. Wietse Mulder — Founder And Managing Partner, Myosotis Investments
“Within the Demcon group, we have worked closely with Scinus to industrialize its cell expansion technology into a robust platform for cellular biotherapy manufacturing. It is rewarding to see Scinus reach this level of maturity, and we are pleased that the company is now ready to move decisively into its next phase of growth.”
Dr. Dennis Schipper — Founder And CEO, Demcon
“We are pleased to welcome Myosotis Investments as lead investor in this round and to continue the strong support from our founders and Demcon. This investment brings Scinus to the next level of organizational maturity. With a strengthened governance structure and a market-ready GMP-compliant platform, we are well positioned to execute our commercial roll-out strategy in key markets and move steadily toward profitability.”
Dr. Erik Vossenaar — Incoming CEO, Scinus
